genomes.io

What genomes.io does

Genomes.io (legal entity Genomesio LTD, also branded as GenomesDAO) is a London-based, UK-registered private company founded in 2018 that operates a decentralized genomic data platform combining AMD SEV-ES encrypted "DNA Vaults" with an Ethereum blockchain audit log and a Base-blockchain-based $GENOME utility token. Its core product is a user-controlled vault: individuals can either purchase 30x whole-genome sequencing kits routed through partner laboratories (Dante Genomics, Nebula Genomics; Dante currently listed as temporarily unavailable) or upload existing raw data from 23andMe, MyHeritage, or Ancestry.com into the same vault. Once vaulted, users can run a library of genetic reports covering ancestry, carrier status, health risks, and pharmacogenetics, gated by an iOS/Android authenticator app that mediates access.

The company operates a hybrid GTM motion. Direct-to-consumer revenue is generated from £399 sequencing kit sales (non-refundable, sourced from sequencing partners) and a £199 lifetime subscription that unlocks 50+ polygenic risk assessments and single-variant analyses. A points-based referral program and a $GENOME/$KIT token staking layer (50% APY, redeemable for kits) add a crypto-native growth and retention mechanic. Enterprise revenue is targeted at pharmaceutical, biotechnology, contract research, academic, and patient-organization buyers through "Virtual Labs," which let organizations build custom reports and run query-based research against consented vault data, with the company positioning itself as a compliant (CLIA/CAP partner labs, GDPR/CCPA) intermediary.

Genomes.io has raised approximately $21.6M+ in disclosed funding, including a $20M GEM Digital investment in August 2023 and a June 2024 round co-led by Pantera Capital and Modular Capital, alongside earlier Crowdcube raises. It has partnerships with AMD (encryption), Consensys (Tachyon accelerator and Base ecosystem), and its sequencing providers. The company is led by co-founders Dr. Mark Hahnel (CSO), Aldo de Pape (CEO), and Chris Griffiths (COO), and operates with 11–50 employees. Revenue is not publicly disclosed.

Name

genomes.io

Legal name

Genomesio LTD

Website

https://genomes.io

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Genomes.io is a UK-based decentralized genomic data platform that lets consumers store 30x whole-genome sequences in SEV-ES encrypted vaults and run polygenic risk reports, while selling Virtual Labs to pharma, biotech and research organizations to query consented data.

Ownership category

akta.pro rank

Product category

Genomic Data Platform

NAICS

Medical Laboratories (621511), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Population Genomics & Preventive Precision Health Programs (HLAAANAL)

Keywords

• Genomic data platform
• DNA sequencing services
• Genetic data security
• Decentralized genome storage
• Personal genome analysis

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. DNA Sequencing Kit Sales: Users purchase 30x whole genome sequencing kits from partnered providers (Dante Genomics, Nebula Genomics) through the platform. Revenue realized at point of purchase with no refunds.
2. Lifetime Subscription for Reports: One-time lifetime subscription (£199) granting access to all genetic reports including 50+ polygenic risk assessments and single-variant analyses.
3. $GENOME Token Rewards: Users earn $GENOME tokens for uploading DNA data, referring friends, and running health reports. Token can be traded for sequencing kits, genomic insights, or fiat.
4. $KIT Staking Program: $KIT is a utility token redeemable for genome sequencing kits (valued at $300). Users stake $GENOME to earn $KIT at 50% APY.
5. Virtual Lab Enterprise Services: Organizations (pharma, biotech, research institutions) pay for customized virtual labs enabling genomic research with secure data access, custom report development, and payment systems for receiving query rewards.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Core offering

Genomes.io operates a decentralized genomic data platform that lets individuals store, manage, and monetize their DNA through SEV-ES encrypted vaults. Users can either purchase 30x whole genome sequencing through partner labs or upload existing raw DNA files from 23andMe, MyHeritage, or Ancestry.com. Pharmaceutical, biotech, and academic organizations access verified, consent-based genomic datasets through the Virtual Labs portal to run research studies against encrypted, user-owned data.

Product overview

Genomes.io is a decentralized genomic data platform built on blockchain technology, offering a suite of products centered around user-owned genomic data control. The core product is the DNA Vault using SEV-ES encryption where users securely store their genomic data. Users can either get sequenced through 30x Whole Genome Sequencing (via partner labs Dante Genomics and Nebula Genomics) or upload existing data from 23andMe, MyHeritage, or Ancestry.com. The Genetic Reports module provides 50+ polygenic risk assessments and single-variant analyses. For enterprise customers, Virtual Labs enables pharmaceutical and research organizations to query genomic databases with participant consent. The $GENOME token powers a reward system where users earn tokens for data contributions, with staking via the $KIT token providing 50% APY. The Genomes.io Authenticator mobile app provides user-controlled access management to DNA Vaults.

Differentiator

Problem solved

Functional benefit

Brands

• Virtual Labs: Customised virtual labs for organizations advancing genomics research, allowing development of custom reports, bespoke vault environments, and payment systems for research queries.

Products and services

• DNA Vault

Quantifiable outcome

• Reads all 3 billion base pairs at 30x coverage vs genotyping reading only 0.002% or exome sequencing reading 1.5%
• +1 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability3 records

Feature7 records

Partnerships

Four partnerships are on record, tiered key and core.

• AMDkeyTechnology or IntegrationCollaboration to bring state-of-the-art encryption technology to genomic data storage. First-of-its-kind innovation partnership for enhanced data security.
• ConsensyskeyGTM or Marketing PartnerGenomes.io was part of the Consensys Incubator Tachyon program, gaining access to global web3 ecosystem and blockchain expertise.
• Dante GenomicscoreTechnology or IntegrationCAP accredited and CLIA compliant 30x whole genome sequencing provider. Provides end-to-end privacy-preserving workflows with data uploaded directly to user DNA Vaults. Currently listed as temporarily unavailable.
• Nebula GenomicscoreTechnology or IntegrationSequencing provider offering 30x whole genome sequencing with 14-week turnaround. Sample return address: 711 Stewart Ave, Suite 200, Garden City, NY 11530, USA.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nebula Genomics: Founded by George Church, Nebula Genomics offers 30x whole-genome sequencing with a privacy-focused, user-controlled data model on blockchain. Direct D2C competitor and current sequencing partner for Genomes.io, sharing both product positioning and technology stack philosophy.
• Dante Genomics: Global whole-genome sequencing provider offering 30x WGS with CLIA/CAP compliance and direct-to-consumer reports. Currently a sequencing partner for Genomes.io but also a competitive D2C sequencing option for the same consumer.
• Veritas Genetics: Whole-genome sequencing provider offering clinical and consumer-grade WGS with health-risk reporting. Overlaps with Genomes.io on sequencing depth, report library, and D2C positioning.
• Sequencing.com: Genetic data platform offering app marketplace and report ecosystem atop user-uploaded DNA data. Closely comparable business model to Genomes.io's vault-plus-reports approach, including support for uploads from major testing services.

Broad incumbents

• 23andMe: Largest consumer genetic testing brand with tens of millions of genotyped users, ancestry and health reports, and a therapeutics pipeline. Competes for the same health-conscious consumer and is a data-source integration for Genomes.io's upload feature.
• Ancestry.com: Dominant consumer genealogy platform with the largest autosomal DNA database and integrated family-tree product. Competes for consumer attention in genetic insights and is an upload integration for Genomes.io.
• MyHeritage: Global consumer DNA testing and genealogy platform with strong European footprint. Competes in the same D2C genetic-testing category and is also an upload integration source for Genomes.io's vault.

Emerging players

• Color Genomics: Clinical-grade genetic testing company focused on hereditary cancer, pharmacogenomics, and population-health programs for employers and health systems. Adjacent in polygenic and pharmacogenomic reporting, with strong enterprise distribution that Genomes.io's Virtual Labs is targeting.
• LunaDNA: Community-owned genomic and health-data sharing platform that compensates members via shares for data contribution. Conceptually aligned with Genomes.io's user-owned-data and token-reward model, making it a comparable decentralized data-network play.
• EncrypGen: Blockchain-based genomic data marketplace where researchers pay DNA holders for access to their data. Closely comparable token-incentivized data-sharing model and competitor in the decentralized-genomics-for-research category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/genomesdao
• Facebookfacebook.com/genomesio
• LinkedInlinkedin.com/company/genomes-io

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about genomes.io